ScholarDeck

Cohort studyEye (London, England) · 2021

A 12-month prospective study to evaluate the efficacy of using the treat-and-extend regimen with intravitreal aflibercept as a Second-Line Treatment for Diabetic Macular Oedema (the TADI Study).

Liran Tiosano, Rita Ehrlich, Yoreh Barak … Itay Chowers

EndocrinologyCohort study

Macular thickness was 303 ± 67 μm at week 52.

A 12-month prospective study to evaluate the efficacy of using the treat-and-extend regimen with intravitreal aflibercept as a Second-Line Treatment for Diabetic Macular Oedema (the TADI Study).

Liran Tiosano … Itay Chowers

Eye (London, England) · 2021

Purpose

To evaluate the efficacy of intravitreal aflibercept as a second-line therapy in eyes with persistent diabetic macular oedema (diabetic macular oedema) despite receiving initial bevacizumab treatment.

Methods

A prospective multicentre study was conducted in nine academic clinics in Israel.

n = 48 eyes

Results

Average central macular thickness was lower at 52 weeks.

468μm

baseline

303μm

52 weeks

More results

Patients received a mean (±SD) of 7.9 ± 3.5 bevacizumab injections before enrolment.

Twenty (46%) eyes met the treat-and-extend criteria and received a mean (±SD) of 10.9 ± 2 aflibercept injections.

“

Conclusion · 1 of 2

Eyes with persistent diabetic macular oedema following initial bevacizumab therapy had a marked reduction in macular thickness and improved visual acuity following 1 year of treatment with intravitreal aflibercept.

Conclusion · 2 of 2

Less than half of the patients met eligibility criteria for extension of the treatment interval; for these patients, the treat-and-extend regimen resulted in a maximum treatment interval of 10 weeks during the first year.

Post

A 12-month prospective study to evaluate the efficacy of using the treat-and-extend regimen with intravitreal aflibercept as a Second-Line Treatment for Diabetic Macular Oedema (the TADI Study).

Macular thickness was 303 ± 67 μm at week 52.

Related papers